BRPI1006076B8 - composições farmacêuticas - Google Patents

composições farmacêuticas

Info

Publication number
BRPI1006076B8
BRPI1006076B8 BRPI1006076A BRPI1006076A BRPI1006076B8 BR PI1006076 B8 BRPI1006076 B8 BR PI1006076B8 BR PI1006076 A BRPI1006076 A BR PI1006076A BR PI1006076 A BRPI1006076 A BR PI1006076A BR PI1006076 B8 BRPI1006076 B8 BR PI1006076B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
compositions
adhesions
scars
enhance
Prior art date
Application number
BRPI1006076A
Other languages
English (en)
Inventor
Münnich Mattias
Mahlapuu Margit
Sjöstrand Veronika
Original Assignee
Pergamum Ab
Pharmasurgics In Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pergamum Ab, Pharmasurgics In Sweden Ab filed Critical Pergamum Ab
Publication of BRPI1006076A2 publication Critical patent/BRPI1006076A2/pt
Publication of BRPI1006076B1 publication Critical patent/BRPI1006076B1/pt
Publication of BRPI1006076B8 publication Critical patent/BRPI1006076B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições farmacêuticas. a presente invenção refere-se a composições farmacêuticas que intensificam o efeito terapêutico de peptídeos biologicamente ativos, especialmente peptídeos derivados de lactoferrina humana. as composições são úteis para o tratamento e/ou prevenção de feridas, cicatrizes e aderências pós-cirúrgicas.
BRPI1006076A 2009-01-13 2010-01-12 composições farmacêuticas BRPI1006076B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0900031-6 2009-01-13
SE0900031 2009-01-13
PCT/EP2010/050284 WO2010081800A2 (en) 2009-01-13 2010-01-12 New pharmaceutical compositions

Publications (3)

Publication Number Publication Date
BRPI1006076A2 BRPI1006076A2 (pt) 2016-04-19
BRPI1006076B1 BRPI1006076B1 (pt) 2020-10-06
BRPI1006076B8 true BRPI1006076B8 (pt) 2021-05-25

Family

ID=42340142

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006076A BRPI1006076B8 (pt) 2009-01-13 2010-01-12 composições farmacêuticas

Country Status (14)

Country Link
US (4) US20110306565A1 (pt)
EP (1) EP2387390B1 (pt)
JP (1) JP5646507B2 (pt)
KR (1) KR101406743B1 (pt)
CN (1) CN102271658B (pt)
AU (1) AU2010205751B2 (pt)
BR (1) BRPI1006076B8 (pt)
CA (1) CA2748860C (pt)
ES (1) ES2400466T3 (pt)
MX (1) MX2011007462A (pt)
PL (1) PL2387390T3 (pt)
RU (1) RU2501566C2 (pt)
WO (1) WO2010081800A2 (pt)
ZA (1) ZA201105806B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400466T3 (es) 2009-01-13 2013-04-10 Pergamum Ab Composiciones que contienen ácido hialurónico para el tratamiento de heridas, cicatrices y la formación de adherencias postquirúrgicas
WO2012057381A1 (ko) * 2010-10-29 2012-05-03 주식회사 휴메딕스 히알루론산 및 ｌ-아르기닌을 함유하는 유착방지제
EP2481751A1 (en) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
WO2012154738A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition and method to improve intestinal health
FR3002452B1 (fr) * 2013-02-28 2016-02-12 Dermaconcept Jmc Composition dermatologique antimicrobienne topique
CN111281978A (zh) * 2019-08-19 2020-06-16 上海交通大学医学院附属第九人民医院 透明质酸基载体及其制备方法在抗瘢痕中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US5080893A (en) 1988-05-31 1992-01-14 University Of Florida Method for preventing surgical adhesions using a dilute solution of polymer
SE8900586L (sv) 1989-02-21 1990-08-22 Pharmacia Ab Komposition och foerfarande foer att foerhindra adhesion mellan kroppsvaevnader
JP2818056B2 (ja) * 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
IT1263394B (it) * 1993-07-30 1996-08-05 Fidia Advanced Biopolymers Srl Composizioni farmaceutiche per uso topico a base di acido ialuronico e suoi derivati
JPH0881387A (ja) * 1994-09-09 1996-03-26 Morinaga Milk Ind Co Ltd 創傷治癒剤
US5690961A (en) 1994-12-22 1997-11-25 Hercules Incorporated Acidic polysaccharides crosslinked with polycarboxylic acids and their uses
RU2177332C2 (ru) 1995-08-29 2001-12-27 Фидиа Адвансд Биополимерз, С.Р.Л. Биоматериал для предотвращения послеоперационных спаек, включающий производные гиалуроновой кислоты (варианты) и способ предотвращения послеоперационных спаек ткани
US6037331A (en) 1996-07-19 2000-03-14 Poly-Med, Inc. Compositions for prevention of inflammation and adhesion formation uses thereof
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
ATE259654T1 (de) * 1998-06-26 2004-03-15 Nutricia Nv Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
SE9804614A0 (en) * 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
US7218503B2 (en) 1998-09-30 2007-05-15 Lam Research Corporation Method of determining the correct average bias compensation voltage during a plasma process
US6521223B1 (en) 2000-02-14 2003-02-18 Genzyme Corporation Single phase gels for the prevention of adhesions
WO2002009792A1 (en) 2000-07-28 2002-02-07 Anika Therapeutics, Inc. Bioabsorbable composites of derivatized hyaluronic acid
KR100375299B1 (ko) 2000-10-10 2003-03-10 주식회사 엘지생명과학 히알루론산의 가교결합형 아마이드 유도체와 이의 제조방법
CA2430130A1 (en) 2000-11-28 2002-06-06 Focal, Inc. Polyalkylene glycol viscosity-enhancing polymeric formulations
EP1284143A1 (en) * 2001-08-17 2003-02-19 Sifi S.p.A A process for the preparation of pharmaceutical formulations containing lactoferrin description
SE0200667D0 (sv) * 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
KR100523953B1 (ko) 2002-08-27 2005-10-25 주식회사 엘지생명과학 천연다당류와 히알루론산의 마이크로비드 및 이의 제조 방법
BRPI0413833A (pt) * 2003-09-11 2006-10-24 Novozymes As célula hospedeira microbiana recombinante, construção de ácido nucleico, método para produzir uma enzima e/ou um agente antimicrobiano, produto de fusão, aditivo e composição de ração animal, animal não humano transgênico ou produtos ou elementos deste, usos do produto de fusão, da co-expressão de um agente antimicrobiano e uma enzima, e de um peptìdeo de proteção, e, método para identificar um peptìdeo de proteção
US7455248B2 (en) 2004-03-17 2008-11-25 Genzyme Corporation Powder delivery device
ITPD20040245A1 (it) 2004-10-08 2005-01-08 Fidia Advanced Biopolymers Srl Biomateriali costituiti da acido ialuronico solfatato e gellano utilizzabili nella prevenzione delle adesioni spinali
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
WO2007009062A2 (en) * 2005-07-13 2007-01-18 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
EP2050461A1 (en) * 2007-10-19 2009-04-22 PharmaSurgics in Sweden AB Peptides based on the sequence of human lactoferrin and their use
ES2400466T3 (es) 2009-01-13 2013-04-10 Pergamum Ab Composiciones que contienen ácido hialurónico para el tratamiento de heridas, cicatrices y la formación de adherencias postquirúrgicas

Also Published As

Publication number Publication date
AU2010205751B2 (en) 2013-05-02
HK1164701A1 (en) 2012-09-28
EP2387390B1 (en) 2012-11-28
CN102271658A (zh) 2011-12-07
US20180200341A1 (en) 2018-07-19
US11000574B2 (en) 2021-05-11
WO2010081800A3 (en) 2010-11-25
CN102271658B (zh) 2013-06-12
BRPI1006076B1 (pt) 2020-10-06
CA2748860C (en) 2014-09-23
JP5646507B2 (ja) 2014-12-24
CA2748860A1 (en) 2010-07-22
US20200188490A1 (en) 2020-06-18
RU2011133224A (ru) 2013-02-20
PL2387390T3 (pl) 2013-12-31
ZA201105806B (en) 2012-04-25
BRPI1006076A2 (pt) 2016-04-19
US20110306565A1 (en) 2011-12-15
US10471129B2 (en) 2019-11-12
WO2010081800A2 (en) 2010-07-22
MX2011007462A (es) 2011-08-03
RU2501566C2 (ru) 2013-12-20
US9878019B2 (en) 2018-01-30
EP2387390A2 (en) 2011-11-23
JP2012515151A (ja) 2012-07-05
ES2400466T3 (es) 2013-04-10
AU2010205751A1 (en) 2011-07-28
KR101406743B1 (ko) 2014-06-20
US20140349949A1 (en) 2014-11-27
KR20110114610A (ko) 2011-10-19

Similar Documents

Publication Publication Date Title
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
BR112017017727A2 (pt) heterociclos bicíclicos como inibidores de fgfr4
UA107783C2 (en) Isoindoline compounds for use in treating cancer
BRPI0906710B8 (pt) peptídeo derivado de pres modificado hidrofóbico de vírus da hepatite b (hbv) , peptídeo e composição farmacêutica
IN2012DN00971A (pt)
BR112014019704A8 (pt) Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo
EP4414376A3 (en) Novel depsipeptide and uses thereof
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
BR112014015908A2 (pt) composição
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
MX2013013913A (es) Polipeptidos.
EP2415763A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF GLAUCOMA
BR112013002319A2 (pt) compostos e métodos para reparo da pele
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
BRPI1014978A2 (pt) método de tratamento do câncer e composição farmacêutica.
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
MX376183B (es) Composiciones para el tratamiento de rosacea.
GEP201606514B (en) Apoptosis inhibitors and usage thereof
MX2016007626A (es) Peptido antimicrobiano y usos del mismo.
BR112013018365A2 (pt) "peptídeos derivados da lactoferrina humana, uso dos mesmos e composição farmacêutica"
EA201200428A1 (ru) Композиция и способ для лечения ожирения
HK1202811A1 (en) Compositions for preventing or treating adverse reactions of egfr inhibition
TR201004464A2 (tr) Kemik erimesi için formülasyon.
MX2011007462A (es) Composiciones que contienen acido hialuronico para el tratamiento de heridas, cicatrices, formacion de dahesiones postquirurgicas.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PERGAMUM AB (SE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: PERGAMUM AB (SE)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2809 DE 05-11-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.